What is MEDICINE MAN TECH INC's earnings per share (EPS)?

MEDICINE MAN TECH INC (SHWZ) reported diluted earnings per share of -$0.66 for fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MEDICINE MAN TECH (SHWZ) Financials

SHWZ OTC

FY2023 annual

Revenue $172.4M +8.2% YoY

Net Income -$34.5M n/m YoY

EPS (Diluted) -$0.66 n/m YoY

Free Cash Flow $4.3M n/m YoY

Market Cap $802 as of Oct 23, 2026

Price / Sales 0.0x on $172.4M revenue, FY2023

Price / Earnings n/m net loss, so no earnings multiple, FY2023

Price / Book 0.0x on $119.3M equity, Q4 FY2023

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2023, ended Dec 31, 2023 Reported Mar 27, 2024 Currency USD FYE December

Newest figures come from the 10-K for FY2023, filed Mar 27, 2024. Each column of the statement tables below links to the filing it was taken from.

MEDICINE MAN TECH INC (SHWZ) reported $172.4M in revenue for fiscal year 2023, up 8.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SHWZ FY2023 2026-10-25

Sales are still expanding, but direct costs and overhead are absorbing the growth while liabilities increasingly finance the balance sheet.

From FY2022 to FY2023, the net loss widened from $18.5M to $34.5M even as operating cash flow rose. That split, alongside depreciation and amortization rising 96.4%, suggests a larger noncash or below-operating-line drag rather than a simple collapse in cash-generating operations.

Cost of revenue rose 21.9% while sales rose 8.2%, showing direct costs outpaced sales. Gross margin then fell 6.3 percentage points to 44.1%, so added sales produced less gross profit.

Liabilities rose 25.2% while equity fell 9.7% in FY2023. That left debt-to-equity at 1.3x and current ratio at 1.0x, while operating cash flow of $12.2M exceeded capital expenditures of $7.9M, producing free cash flow of $4.3M.

Financial Health Signals

Financial health score not available

MEDICINE MAN TECH INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

0.19

MEDICINE MAN TECH INC scores 0.19, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $80.8M against total assets of $358.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

2/9

MEDICINE MAN TECH INC passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Mixed

N/A

MEDICINE MAN TECH INC reported a net loss of $34.5M while generating $12.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$43.3M

YoY+7.9%

QoQ-7.3%

5Y CAGR+82.5%

MEDICINE MAN TECH INC generated $43.3M in revenue in Q4 2023. This represents an increase of 7.9% from the same quarter a year earlier. Against the prior quarter it is down 7.3%.

EBITDA

-$11.0M

YoY-375.7%

QoQ-179.8%

5Y CAGRn/m

MEDICINE MAN TECH INC's EBITDA was -$11.0M in Q4 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 375.7% from the same quarter a year earlier. Against the prior quarter it is down 179.8%.

Net Income

-$29.4M

YoYn/m

QoQn/m

5Y CAGRn/m

MEDICINE MAN TECH INC reported a net loss of $29.4M in Q4 2023. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$0.52

MEDICINE MAN TECH INC earned -$0.52 per diluted share (EPS) in Q4 2023.

Cash & Balance Sheet

Free Cash Flow

$2.4M

YoY-50.6%

QoQ-51.8%

MEDICINE MAN TECH INC generated $2.4M in free cash flow in Q4 2023, representing cash available after capex. This represents a decrease of 50.6% from the same quarter a year earlier. Against the prior quarter it is down 51.8%.

Cash & Debt

$19.2M

YoY-50.6%

QoQ-1.9%

5Y CAGR+126.7%

MEDICINE MAN TECH INC held $19.2M in cash against $153.3M in long-term debt as of Q4 2023.

Shares Outstanding

77M

YoY+40.3%

MEDICINE MAN TECH INC had 77M shares outstanding in Q4 2023. This represents an increase of 40.3% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q4 2023.

Margins & Returns

Gross Margin

16.2%

YoY-37.9pp

QoQ-29.6pp

5Y change-20.1pp

MEDICINE MAN TECH INC's gross margin was 16.2% in Q4 2023, indicating the percentage of revenue retained after direct costs. This is down 37.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 29.6 percentage points.

Operating Margin

-37.5%

YoY-31.3pp

QoQ-56.6pp

5Y change-20.2pp

MEDICINE MAN TECH INC's operating margin was -37.5% in Q4 2023, reflecting core business profitability. This is down 31.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 56.6 percentage points.

Net Margin

-67.8%

YoY+0.3pp

QoQ-67.1pp

MEDICINE MAN TECH INC's net profit margin was -67.8% in Q4 2023, showing the share of revenue converted to profit. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 67.1 percentage points.

Return on Equity

-24.6%

YoY-3.9pp

QoQ-24.4pp

5Y change0.0pp

MEDICINE MAN TECH INC's quarterly ROE was -24.6% in Q4 2023: one quarter's net income over shareholder equity, not annualized. This is down 3.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 24.4 percentage points.

Capital Allocation

Capital Expenditures

$1.1M

YoY-26.6%

QoQ-46.7%

MEDICINE MAN TECH INC invested $1.1M in capex in Q4 2023, funding long-term assets and infrastructure. This represents a decrease of 26.6% from the same quarter a year earlier. Against the prior quarter it is down 46.7%.

R&D Spending

Not reported for Q4 2023.

Share Buybacks

Not reported for Q4 2023.

SHWZ Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SHWZ quarterly income statement

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$172.4M+8.2%	$159.4M+47.0%	$108.4M+351.7%	$24.0M+93.5%	$12.4M+31.3%	$9.4M+167.5%	$3.5M+459.0%	$631K-24.4%	$836K+231.8%	$252K
Cost of Revenue	$96.4M+21.9%	$79.1M+33.9%	$59.1M+242.9%	$17.2M+126.2%	$7.6M+195.5%	$2.6M+149.4%	$1.0M+123.7%	$462K	N/A	N/A
Gross Profit	$76.0M-5.3%	$80.3M+62.7%	$49.4M+628.5%	$6.8M+41.6%	$4.8M-30.3%	$6.9M+208.2%	$2.2M+1215.8%	$169K-73.0%	$626K+248.0%	$180K
SG&A Expenses	$39.9M+37.5%	$29.0M+74.7%	$16.6M+267.3%	$4.5M+100.0%	$2.3M+105.2%	$1.1M-19.6%	$1.4M+257.9%	$383K+2.6%	$373K+168.4%	$139K
Operating Income	$3.3M-74.4%	$12.9M+23.5%	$10.4Mn/m	-$22.9Mn/m	-$17.1M-887.1%	$2.2Mn/m	-$5.2Mn/m	-$1.2M-1377.9%	$90Kn/m	-$29K
EBITDA	$24.2M+3.0%	$23.5M+23.9%	$19.0Mn/m	-$22.4Mn/m	-$17.0M-855.7%	$2.3Mn/m	-$5.2Mn/m	-$1.1M-1272.6%	$97Kn/m	-$28K
Interest Expense	N/A	N/A	$7.0M+16818.2%	$41K	N/A	$0-100.0%	$86K+286.6%	$22Kn/m	$0-100.0%	$1K
Income Tax	$19.7M+32.5%	$14.9M+238.9%	$4.4Mn/m	-$899Kn/m	-$583K-200.0%	$583Kn/m	$0n/m	$0-100.0%	$12K+296.9%	$3K
Net Income	-$34.5Mn/m	-$18.5M-227.2%	$14.5Mn/m	-$19.4Mn/m	-$17.0M-1889.0%	$949Kn/m	-$5.4Mn/m	-$1.5M-1807.6%	$86Kn/m	-$30K
EPS (Basic)	-$0.66n/m	-$0.49	$0.17n/m	-$0.47n/m	-$0.50-1350.0%	$0.04n/m	-$0.23	-$0.14-1500.0%	$0.01n/m	$0.00
EPS (Diluted)	-$0.66n/m	-$0.49	-$0.06n/m	-$0.47n/m	-$0.50-1766.7%	$0.03n/m	-$0.23	-$0.14-1500.0%	$0.01n/m	$0.00
Diluted Shares (Avg)	65M+20.3%	54M	101M+145.9%	41M+22.2%	34M+21.5%	28M+20.8%	23M	N/A	N/A	N/A

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Revenue	$43.3M+7.9%	$46.7M+8.2%	$42.4M-4.3%	$40.0M+25.9%	$40.1M+51.4%	$43.2M+35.7%	$44.3M+44.0%	$31.8M+64.3%
Cost of Revenue	$36.3M+65.6%	$25.3M+46.9%	$17.9M-6.5%	$17.0M-18.6%	$21.9M+52.5%	$17.2M+2.7%	$19.1M+20.7%	$20.8M+72.4%
Gross Profit	$7.0M-67.6%	$21.4M-4.6%	$24.5M-2.5%	$23.0M+110.6%	$21.7M+78.9%	$22.5M+49.3%	$25.2M+68.8%	$10.9M+50.8%
SG&A Expenses	$11.2M+25.8%	$9.6M+46.2%	$8.8M+32.6%	$10.2M+49.0%	$8.9M+193.9%	$6.6M+17.9%	$6.7M+38.9%	$6.9M+114.9%
Operating Income	-$16.2Mn/m	$8.9M-19.7%	$5.0M-45.1%	$5.6Mn/m	-$2.5M-169.3%	$11.1M+189.7%	$9.0M+103.5%	-$4.8Mn/m
EBITDA	-$11.0M-375.7%	$13.8M+15.8%	$9.6M-2.3%	$11.8Mn/m	$4.0M-9.5%	$11.9M+74.9%	$9.9M+32.2%	-$2.2M-836.0%
Income Tax	$4.5M+23.5%	$5.4M-2.7%	$5.1M+16.7%	$4.7M+270.0%	$3.6M+51.7%	$5.6M+326.1%	$4.4M+1828.4%	$1.3M+175.9%
Net Income	-$29.4Mn/m	-$322K-117.8%	-$6.6M-119.5%	$1.7Mn/m	-$27.3M-313.1%	$1.8M+86.8%	$33.8M+674.4%	-$26.8Mn/m
EPS (Basic)	-$0.52	-$0.02n/m	-$0.15	-$0.01	N/A	$0.00	$0.65	-$0.61n/m
EPS (Diluted)	-$0.52	-$0.03n/m	-$0.15	-$0.06	N/A	$0.00	$0.24	-$0.61n/m
Diluted Shares (Avg)	N/A	87M-36.8%	61M	102M	N/A	138M	133M	47M

Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.

SHWZ Balance Sheet

SHWZ quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$358.1M+10.9%	$322.9M+13.3%	$285.0M+303.3%	$70.7M+119.3%	$32.2M+76.9%	$18.2M+63.7%	$11.1M+1429.5%	$728K+52.6%	$477K+52.7%	$312K
Current Assets	$53.7M-25.2%	$71.7M-42.3%	$124.4M+1974.3%	$6.0M-61.5%	$15.6M+618.2%	$2.2M+56.5%	$1.4M+103.0%	$682K+60.6%	$425K+38.0%	$308K
Cash & Equivalents	$19.2M-50.6%	$38.9M-63.4%	$106.4M+8541.7%	$1.2M-89.6%	$11.9M+3583.7%	$322K-57.0%	$749K+113.0%	$352K+34.1%	$262K+380.9%	$55K
Short-Term Investments	$456K+0.4%	$454K-8.0%	$494Kn/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$14Kn/m	$0n/m	$0
Inventory	$25.8M+14.3%	$22.6M+102.8%	$11.1M+324.6%	$2.6M+282.4%	$685K+40.0%	$489K+361.2%	$106Kn/m	$0	N/A	N/A
Accounts Receivable	$4.3M-4.7%	$4.5M+15.6%	$3.9M+204.4%	$1.3M+305.5%	$313K-73.5%	$1.2M+155.9%	$461K+1745.4%	$25K-70.1%	$84Kn/m	$0
Long-Term Investments	$2.0M0.0%	$2.0M+305.2%	$494K+78.3%	$277K-32.0%	$407Kn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Goodwill	$67.5M-28.7%	$94.6M+118.4%	$43.3M-18.3%	$53.0M+331.1%	$12.3M0.0%	$12.3M+32.2%	$9.3Mn/m	$0	N/A	N/A
Total Liabilities	$238.9M+25.2%	$190.7M+25.9%	$151.5M+423.9%	$28.9M+411.8%	$5.6M+392.1%	$1.1M+191.9%	$393K-64.4%	$1.1M+4938.5%	$22K-4.0%	$23K
Current Liabilities	$55.5M+17.0%	$47.4M+4.7%	$45.3M+266.2%	$12.4M+121.4%	$5.6M+386.3%	$1.1M+242.7%	$335K+13.9%	$294K+1242.4%	$22K-4.0%	$23K
Non-Current Liabilities	$183.4M+27.9%	$143.3M+35.0%	$106.2M+541.8%	$16.5M+24670.4%	$67Kn/m	$0-100.0%	$58K-92.8%	$810Kn/m	$0n/m	$0
Long-Term Debt	$153.3M+22.1%	$125.5M+28.8%	$97.5M+601.2%	$13.9M	N/A	N/A	$0-100.0%	$810Kn/m	$0	N/A
Total Equity	$119.3M-9.7%	$132.2M-1.1%	$133.6M+219.7%	$41.8M+57.2%	$26.6M+55.7%	$17.1M+59.0%	$10.7Mn/m	-$376K-182.7%	$455K+57.1%	$290K
Retained Earnings	-$80.8Mn/m	-$46.2Mn/m	-$27.8Mn/m	-$42.3Mn/m	-$22.8Mn/m	-$5.8Mn/m	-$6.8Mn/m	-$1.4M-2624.4%	$56Kn/m	-$30K

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Total Assets	$358.1M+10.9%	$370.6M+12.4%	$369.0M+16.0%	$323.4M+1.7%	$322.9M+13.3%	$329.6M+69.2%	$318.1M+73.5%	$318.0M+75.7%
Current Assets	$53.7M-25.2%	$64.4M-10.1%	$66.5M-0.4%	$74.1M+3.8%	$71.7M-42.3%	$71.6M+88.6%	$66.8M+88.0%	$71.4M+126.0%
Cash & Equivalents	$19.2M-50.6%	$19.6M-49.3%	$19.9M-41.3%	$35.2M-26.3%	$38.9M-63.4%	$38.7M+82.9%	$33.9M+60.3%	$47.7M+107.6%
Short-Term Investments	$456K+0.4%	$456K+1.1%	$456Kn/m	$456Kn/m	$454K-8.0%	$451Kn/m	$0n/m	$0n/m
Inventory	$25.8M+14.3%	$32.8M+53.9%	$33.8M+74.6%	$25.6M+56.1%	$22.6M+102.8%	$21.3M+99.4%	$19.4M+111.0%	$16.4M+193.1%
Accounts Receivable	$4.3M-4.7%	$5.0M-2.4%	$6.2M+7.4%	$4.6M+9.4%	$4.5M+15.6%	$5.2M+46.6%	$5.8M+79.5%	$4.2M+77.4%
Long-Term Investments	$2.0M0.0%	$2.0Mn/m	$2.0M+316.9%	$2.0M+312.4%	$2.0M+305.2%	$0-100.0%	$480K-3.7%	$485K-1.3%
Goodwill	$67.5M-28.7%	$76.6M-23.1%	$76.0M-29.6%	$64.5M-45.7%	$94.6M+118.4%	$99.6M+136.6%	$108.0M+160.1%	$118.7M+192.8%
Total Liabilities	$238.9M+25.2%	$224.8M+31.7%	$220.9M+37.1%	$189.3M-6.4%	$190.7M+25.9%	$170.7M+121.7%	$161.2M+125.7%	$202.2M+182.0%
Current Liabilities	$55.5M+17.0%	$50.4M+67.8%	$49.8M+74.3%	$42.0M-40.3%	$47.4M+4.7%	$30.0M+115.4%	$28.6M+118.1%	$70.3M+435.6%
Non-Current Liabilities	$183.4M+27.9%	$174.4M+24.0%	$171.1M+29.0%	$147.3M+11.6%	$143.3M+35.0%	$140.7M+123.1%	$132.6M+127.4%	$131.9M+125.2%
Long-Term Debt	$153.3M+22.1%	$150.9M+22.8%	$148.9M+22.9%	$128.2M+8.8%	$125.5M+28.8%	$122.9M+107.4%	$121.1M+123.2%	$117.9M+117.3%
Total Equity	$119.3M-9.7%	$145.8M-8.6%	$148.1M-5.9%	$134.1M+10.9%	$132.2M-1.1%	$159.5M+35.5%	$157.3M+40.6%	$121.0M+10.7%
Retained Earnings	-$80.8Mn/m	-$51.4Mn/m	-$51.1Mn/m	-$44.5Mn/m	-$46.2Mn/m	-$18.9Mn/m	-$20.7Mn/m	-$54.6Mn/m

SHWZ Cash Flow Statement

SHWZ quarterly cash flow statement

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	$12.2M+82.3%	$6.7M-20.3%	$8.4Mn/m	-$9.8Mn/m	-$7.6Mn/m	-$1.2Mn/m	-$674Kn/m	-$741K-345.6%	$302Kn/m	-$205K
Depreciation & Amortization	$20.9M+96.4%	$10.7M+24.3%	$8.6M+1699.6%	$477K+672.3%	$62K-24.7%	$82K+28.6%	$64K+266.9%	$17K+162.5%	$7K+1079.7%	$561
Stock-Based Compensation	$3.6M+33.8%	$2.7M-46.9%	$5.0M-38.8%	$8.2M+13.1%	$7.3M+399.5%	$1.5M-69.7%	$4.8M+666.2%	$627K+686.7%	$80K+47.0%	$54K
Capital Expenditures	$7.9M-43.8%	$14.0M+148.5%	$5.6M+634.0%	$768K	N/A	$20K-92.2%	$256K+2257.6%	$11K-80.0%	$54Kn/m	$0
Free Cash Flow	$4.3Mn/m	-$7.3M-365.0%	$2.8Mn/m	-$10.6M	N/A	-$1.2Mn/m	-$930Kn/m	-$752K-403.8%	$248Kn/m	-$205K
Investing Cash Flow	-$26.4Mn/m	-$75.0Mn/m	-$81.2Mn/m	-$33.2Mn/m	-$1.1Mn/m	-$257Kn/m	-$34K-262.6%	$21K	N/A	N/A
Financing Cash Flow	-$5.5M-747.4%	$844K-99.5%	$177.9M+457.8%	$31.9M+57.9%	$20.2M+1920.3%	$1.0M-9.5%	$1.1M+36.4%	$810K	N/A	N/A
Dividends Paid	N/A	N/A	N/A	$60K	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Operating Cash Flow	$3.5M-44.9%	$6.9M-32.6%	$2.7Mn/m	-$880K-124.3%	$6.3M+74.7%	$10.3M+201.2%	-$13.5Mn/m	$3.6M+113.3%
Depreciation & Amortization	$5.2M+124.4%	$4.9M+510.9%	$4.7M+468.9%	$6.2M+142.1%	$2.3M+192.4%	$798K-73.1%	$822K-72.8%	$2.5M+41.9%
Stock-Based Compensation	N/A	-$2.4M-2540.6%	$2.8M+307.8%	$215K-78.4%	N/A	$100K-91.9%	$698K-39.5%	$991K-33.2%
Capital Expenditures	$1.1M-26.6%	$2.1M-62.1%	$1.8M-59.6%	$2.9M+10.2%	$1.5M-15.4%	$5.4M+103.8%	$4.4M+677.6%	$2.6M+317.5%
Free Cash Flow	$2.4M-50.6%	$4.9M+0.4%	$893Kn/m	-$3.8M-487.5%	$4.8M+162.4%	$4.9M+546.5%	-$17.9Mn/m	$979K-8.1%
Investing Cash Flow	-$1.2Mn/m	-$4.7Mn/m	-$17.6Mn/m	-$2.9Mn/m	-$5.6Mn/m	-$5.4Mn/m	-$1.6Mn/m	-$62.3Mn/m
Financing Cash Flow	-$2.7Mn/m	-$2.5Mn/m	N/A	N/A	-$437K-100.5%	$0-100.0%	$10.0Mn/m	$28.4M-66.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SHWZ Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SHWZ quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	44.1%-6.3pp	50.4%+4.9pp	45.5%+17.3pp	28.2%-10.3pp	38.6%-34.1pp	72.7%+9.6pp	63.1%+36.3pp	26.8%-48.1pp	74.9%+3.5pp	71.4%
Operating Margin	1.9%-6.2pp	8.1%-1.5pp	9.6%+105.0pp	-95.4%	-137.8%	23.0%	-148.3%	-182.4%	10.8%+22.2pp	-11.4%
Net Margin	-20.0%-8.4pp	-11.6%-25.0pp	13.4%+94.3pp	-80.9%	-136.9%	10.1%	-152.5%	-231.9%	10.3%+22.1pp	-11.9%
Return on Equity	-29.0%-15.0pp	-14.0%-24.8pp	10.9%+57.4pp	-46.5%+17.4pp	-63.9%-69.4pp	5.6%+55.7pp	-50.1%	N/A	18.8%+29.2pp	-10.3%
Return on Assets	-9.7%-3.9pp	-5.7%-10.8pp	5.1%+32.6pp	-27.5%+25.2pp	-52.7%-57.9pp	5.2%+53.5pp	-48.3%+152.8pp	-201.2%-219.2pp	18.0%+27.6pp	-9.6%
Current Ratio	0.97-0.5x	1.51-1.2x	2.75+2.3x	0.49-2.3x	2.79+0.9x	1.89-2.2x	4.13+1.8x	2.32-17.1x	19.38+5.9x	13.48
Debt-to-Equity	1.28+0.3x	0.95+0.2x	0.73+0.4x	0.33	N/A	N/A	0.00	N/A	0.00	N/A
Liabilities-to-Equity	2.00+0.6x	1.44+0.3x	1.13+0.4x	0.69+0.5x	0.21+0.1x	0.070.0x	0.04	N/A	0.050.0x	0.08
Asset Turnover	0.480.0x	0.49+0.1x	0.380.0x	0.340.0x	0.38-0.1x	0.52+0.2x	0.32-0.6x	0.87-0.9x	1.75+0.9x	0.81
FCF Margin	2.5%+7.1pp	-4.6%-7.1pp	2.5%+46.6pp	-44.0%	N/A	-12.6%+13.7pp	-26.3%	-119.1%	29.6%+111.2pp	-81.6%

Metric	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q
Gross Margin	16.2%-37.9pp	45.9%-6.2pp	57.9%+1.0pp	57.6%+23.2pp	54.1%+8.3pp	52.0%+4.7pp	56.8%+8.3pp	34.4%-3.1pp
Operating Margin	-37.5%-31.3pp	19.1%-6.6pp	11.7%-8.7pp	14.1%+29.2pp	-6.2%-19.9pp	25.7%+13.7pp	20.4%+6.0pp	-15.1%-7.4pp
Net Margin	-67.8%+0.3pp	-0.7%-4.9pp	-15.6%-92.0pp	4.4%+88.6pp	-68.1%-116.5pp	4.2%+1.1pp	76.4%+62.2pp	-84.3%-65.4pp
Return on Equity	-24.6%-3.9pp	-0.2%-1.4pp	-4.5%-26.0pp	1.3%+23.4pp	-20.7%-30.3pp	1.1%+0.3pp	21.5%+17.6pp	-22.1%-18.8pp
Return on Assets	-8.2%+0.3pp	-0.1%-0.6pp	-1.8%-12.4pp	0.5%+9.0pp	-8.5%-13.0pp	0.5%0.0pp	10.6%+8.3pp	-8.4%-6.4pp
Current Ratio	0.97-0.5x	1.28-1.1x	1.34-1.0x	1.77+0.8x	1.51-1.2x	2.38-0.3x	2.34-0.4x	1.02-1.4x
Debt-to-Equity	1.28+0.3x	1.03+0.3x	1.01+0.2x	0.960.0x	0.95+0.2x	0.77+0.3x	0.77+0.3x	0.97+0.5x
Liabilities-to-Equity	2.00+0.6x	1.54+0.5x	1.49+0.5x	1.41-0.3x	1.44+0.3x	1.07+0.4x	1.02+0.4x	1.67+1.0x
Asset Turnover	0.120.0x	0.130.0x	0.110.0x	0.120.0x	0.120.0x	0.130.0x	0.140.0x	0.100.0x
FCF Margin	5.4%-6.4pp	10.4%-0.8pp	2.1%+42.6pp	-9.5%-12.6pp	11.9%+5.0pp	11.3%+8.9pp	-40.5%-37.6pp	3.1%-2.4pp

Note: The current ratio is below 1.0 (0.97), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
MEDICINE MAN TECH INC SHWZ	FY2023	$172.4M	-$34.5M	-20.0%	$802	—
BLUM HOLDINGS INC. BLMH	FY2024	$13.0M	$33.1M	N/A	$4.7M	—

Where MEDICINE MAN TECH INC Ranks

Frequently Asked Questions

What is MEDICINE MAN TECH INC's annual revenue?

MEDICINE MAN TECH INC (SHWZ) reported $172.4M in total revenue for fiscal year 2023. This represents a 8.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MEDICINE MAN TECH INC's revenue growing?

MEDICINE MAN TECH INC (SHWZ) revenue grew by 8.2% year-over-year, from $159.4M to $172.4M in fiscal year 2023.

Is MEDICINE MAN TECH INC profitable?

No, MEDICINE MAN TECH INC (SHWZ) reported a net loss of $34.5M in fiscal year 2023, with a net profit margin of -20.0%.

What is MEDICINE MAN TECH INC's EBITDA?

MEDICINE MAN TECH INC (SHWZ) had EBITDA of $24.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does MEDICINE MAN TECH INC have?

As of fiscal year 2023, MEDICINE MAN TECH INC (SHWZ) had $19.2M in cash and equivalents against $153.3M in long-term debt.

What is MEDICINE MAN TECH INC's gross margin?

MEDICINE MAN TECH INC (SHWZ) had a gross margin of 44.1% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.

What is MEDICINE MAN TECH INC's operating margin?

MEDICINE MAN TECH INC (SHWZ) had an operating margin of 1.9% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.

What is MEDICINE MAN TECH INC's net profit margin?

MEDICINE MAN TECH INC (SHWZ) had a net profit margin of -20.0% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.

What is MEDICINE MAN TECH INC's return on equity (ROE)?

MEDICINE MAN TECH INC (SHWZ) has a return on equity of -29.0% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.

What is MEDICINE MAN TECH INC's free cash flow?

MEDICINE MAN TECH INC (SHWZ) generated $4.3M in free cash flow during fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is MEDICINE MAN TECH INC's operating cash flow?

MEDICINE MAN TECH INC (SHWZ) generated $12.2M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

What are MEDICINE MAN TECH INC's total assets?

MEDICINE MAN TECH INC (SHWZ) had $358.1M in total assets as of fiscal year 2023, including both current and long-term assets.

What are MEDICINE MAN TECH INC's capital expenditures?

MEDICINE MAN TECH INC (SHWZ) invested $7.9M in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How many shares does MEDICINE MAN TECH INC have outstanding?

MEDICINE MAN TECH INC (SHWZ) had 77M shares outstanding as of fiscal year 2023.

What is MEDICINE MAN TECH INC's current ratio?

MEDICINE MAN TECH INC (SHWZ) had a current ratio of 0.97 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

What is MEDICINE MAN TECH INC's debt-to-equity ratio?

MEDICINE MAN TECH INC (SHWZ) had a debt-to-equity ratio of 1.28 as of fiscal year 2023. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is MEDICINE MAN TECH INC's liabilities-to-equity ratio?

MEDICINE MAN TECH INC (SHWZ) had a liabilities-to-equity ratio of 2.00 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is MEDICINE MAN TECH INC's return on assets (ROA)?

MEDICINE MAN TECH INC (SHWZ) had a return on assets of -9.7% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

What is MEDICINE MAN TECH INC's P/E ratio?

MEDICINE MAN TECH INC (SHWZ) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2023). The market capitalization is $802 as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MEDICINE MAN TECH INC's price-to-sales ratio?

MEDICINE MAN TECH INC (SHWZ) trades at 0.0x sales, its market capitalization divided by $172.4M revenue, FY2023. The market capitalization is $802 as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is MEDICINE MAN TECH INC's Altman Z-Score?

MEDICINE MAN TECH INC (SHWZ) has an Altman Z-Score of 0.19, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is MEDICINE MAN TECH INC's Piotroski F-Score?

MEDICINE MAN TECH INC (SHWZ) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MEDICINE MAN TECH INC's earnings high quality?

MEDICINE MAN TECH INC (SHWZ) reported a net loss of $34.5M while generating $12.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.